Hematology-Oncology Associates of CNY

Clinical research site in East Syracuse, New York · 5008 BRITTONFIELD PKWY, SUITE 700, EAST SYRACUSE, NY 13057-9248 · (315) 472-7504 · Website

As of September 2026, 16 paid clinical trials are recruiting at Hematology-Oncology Associates of CNY in East Syracuse, New York. Active studies at this site cover conditions such as Acinar Cell Carcinoma, Advanced Cancer and B-Cell Non-Hodgkins Lymphoma. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: September 1, 2026.

New trial at Hematology-Oncology Associates of CNY? We'll email you when one opens.

Recruiting clinical trials at Hematology-Oncology Associates of CNY (16)

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

for Intestinal Neoplasms

200 locations incl. Chandler

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07222800·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

for Metastatic Castration-resistant Prostate Cancer

43 locations incl. Goodyear

Sponsor: Amgen

Sex: Male·Age: 18+

Code: NCT07213674·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

for Breast Cancer

172 locations incl. Daphne

Sponsor: Stemline Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06492616·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

for Carcinoma, Non-Small-Cell Lung

125 locations incl. Daphne

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06667076·Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

for Triple Negative Breast Cancer

124 locations incl. Birmingham

Sponsor: Gilead Sciences

Sex: All·Age: 18+

Code: NCT05633654·Phase 3·Recruiting·Listed Dec 2022

Apply to this trial

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

for B-Cell Non-Hodgkins Lymphoma

33 locations incl. Anchorage

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT06806033·Phase 2·Recruiting·Listed Feb 2025

Apply to this trial

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

for Advanced Cancer

38 locations incl. Birmingham

Sponsor: Artios Pharma Ltd

Sex: All·Age: 18+

Code: NCT04657068·Phase 1, Phase 2·Recruiting·Listed Dec 2020

Apply to this trial

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

for Small-cell Lung Cancer

50 locations incl. Casa Grande

Sponsor: Amgen

Sex: All·Age: 18 - 99

Code: NCT07005128·Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

for Carcinoma, Non-Small-Cell Lung

50 locations incl. Gilbert

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06623422·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

for Multiple Myeloma

66 locations incl. Gilbert

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT05552222·Phase 3·Recruiting·Listed Sep 2022

Apply to this trial

GEMINI-NSCLC: NSCLC Biomarker Study

for Non-Small Cell Lung Cancer

56 locations incl. Birmingham

Sponsor: Tempus AI

Sex: All·Age: 18+

Code: NCT05236114·Recruiting·Listed Feb 2022

Apply to this trial

TEMPUS ARIES: A Biobank Registry Platform Study in Oncology

for Cancer

24 locations incl. Birmingham

Sponsor: Tempus AI

Sex: All·Age: 18 - 99

Code: NCT06207032·Recruiting·Listed Jan 2024

Apply to this trial

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

for Lymphoma

20 locations incl. Duarte

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT06084936·Phase 3·Recruiting·Listed Oct 2023

Apply to this trial

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

for Gastroesophageal Junction

6 locations incl. Tucson

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06469944·Phase 1, Phase 2·Recruiting·Listed Jun 2024

Apply to this trial

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

for Esophageal Squamous Cell Carcinoma

4 locations incl. Tucson

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT05319730·Phase 1, Phase 2·Recruiting·Listed Apr 2022

Apply to this trial

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

for Gastroesophageal Junction

6 locations incl. Tucson

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06445972·Phase 1, Phase 2·Recruiting·Listed Jun 2024

Apply to this trial

Get new-trial alerts for Hematology-Oncology Associates of CNY

We'll email you whenever a new clinical trial starts recruiting at this research site in East Syracuse, NY. Unsubscribe anytime.

More research sites in East Syracuse

Hematology Oncology Associates of Central New York-East Syracuse (12 trials)
Hematology Oncology Associates of Central New York (5 trials)
Hematology Oncology Associates of Central New York, PC (3 trials)
Velocity Clinical Research - Syracuse (3 trials)
Velocity Clinical Research, Syracuse (3 trials)
Child Health Care Associates (3 trials)
Hematology-Oncology Associates of Central NY, P.C. (3 trials)
GSK Investigational Site (2 trials)
Galderma Investigational (2 trials)
Hematology Oncology Association of Central New York (2 trials)

Is this your research site?

This page is built from public ClinicalTrials.gov records. If you work here, we can correct it, send you the patients who apply, and build you a free website from your real studies — verify it with your work email, or read what we do for research sites.

Explore more

Paid clinical trials in East Syracuse, NY · New York clinical trials